Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337799 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2 | |
| SCHEMBL31250298 | 0.75 | POLB (0.54) | SMN1; SMN2ALDH1A1HPGDPOLB | |
| SCHEMBL21140974 | 0.73 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1HPGDPOLB | |
| SCHEMBL188355 | 0.71 | — | — | |
| SCHEMBL2254744 | 0.68 | — | — | |
| SCHEMBL42221 | 0.67 | PHGDH (0.39) | POLB | |
| SCHEMBL193442 | 0.67 | PHGDH (0.34) | POLB | |
| SCHEMBL21124355 | 0.67 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL21039571 | 0.67 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL7008499 | 0.67 | SMN1; SMN2 (0.36) | SMN1; SMN2ALDH1A1HPGDPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163735-B2 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | VIROBAY, INC. (US) | 2009-09-17 | — | — | US | disclosed |
| EP-1866276-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006102423-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2006-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233909-A1 | Sulfonamide compounds as cysteine protease inhibitors | CTSF, CTSS, CSTB | SMN1; SMN2 3114/4885ALDH1A1 2409/4885HPGD 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.